RARE logo

RARE
Ultragenyx Pharmaceutical Inc

2,843
Mkt Cap
$2.57B
Volume
1.56M
52W High
$42.37
52W Low
$18.29
PE Ratio
-4.28
RARE Fundamentals
Price
$26.12
Prev Close
$26.13
Open
$26.05
50D MA
$22.83
Beta
1.10
Avg. Volume
1.69M
EPS (Annual)
-$5.83
P/B
-10.85
Rev/Employee
$490,882.57
$2,833.80
Loading...
Loading...
News
all
press releases
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Wells Fargo & Company Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
Wells Fargo & Company upped their price target on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an "overweight" rating in a research report on Wednesday...
MarketBeat·3d ago
News Placeholder
Wedbush Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a 'neutral' rating for the company in a research report on Wednesday...
MarketBeat·3d ago
News Placeholder
Universal Beteiligungs und Servicegesellschaft mbH Has $323,000 Position in Ultragenyx Pharmaceutical Inc. $RARE
Universal Beteiligungs und Servicegesellschaft mbH decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 84.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,094 shares of the...
MarketBeat·3d ago
News Placeholder
Ultragenyx Pharmaceutical Q1 Earnings Call Highlights
Ultragenyx Pharmaceutical (NASDAQ:RARE) executives said the company is positioned for what Chief Executive Officer Emil Kakkis described as a "transformative" year, pointing to expectations for growing revenue, potential approvals for two gene therapies, and a key late-stage readout for its Angelman...
MarketBeat·4d ago
News Placeholder
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Expectations By $1,000.50 EPS
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $999.00 EPS for the quarter, beating analysts' consensus estimates of ($1.50) by $1,000.50. Ultragenyx Pharmaceutical had a negative return on equity of...
MarketBeat·4d ago
News Placeholder
Ultragenyx Pharmaceutical Q1 2026 Earnings Call Transcript
read more...
Benzinga·4d ago
News Placeholder
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·4d ago
News Placeholder
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.96% and -15.66%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 4,683 Shares
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 4,683 shares of the firm's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $24.90, for a total transaction of $116,606.70. Following the completion of the sale, the chief...
MarketBeat·5d ago
<
1
2
...
>

Latest RARE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.